Tags

Type your tag names separated by a space and hit enter

Cisapride for gastro-oesophageal reflux and peptic oesophagitis.
Arch Dis Child 1987; 62(5):454-7AD

Abstract

Twenty children (age range 75 days-47 months) with reflux oesophagitis entered a random double blind trial in which they received either Cisapride (Janssen Pharmaceutical Ltd), a new prokinetic agent, or an identical placebo syrup. Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry. Oesophagitis was assessed in all patients by histological examination of mucosal specimens taken during oesophagogastroduodenoscopy. Manometry, pH test, and endoscopy with biopsy examination were repeated at the end of the treatment period. Seventeen patients completed the trial, eight of whom were taking the drug and nine the placebo. Mean total clinical score and post-prandial reflux time (% of reflux) significantly improved in patients in the group given Cisapride but not in the group given placebo. Furthermore, there was a significant improvement of the histological oesophagitis score only in the children in the group given Cisapride, whereas placebo was ineffective. It is concluded that Cisapride is a useful agent both for the relief of symptoms of gastro-oesophageal reflux and for the healing of peptic oesophagitis in infancy.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3300570

Citation

Cucchiara, S, et al. "Cisapride for Gastro-oesophageal Reflux and Peptic Oesophagitis." Archives of Disease in Childhood, vol. 62, no. 5, 1987, pp. 454-7.
Cucchiara S, Staiano A, Capozzi C, et al. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1987;62(5):454-7.
Cucchiara, S., Staiano, A., Capozzi, C., Di Lorenzo, C., Boccieri, A., & Auricchio, S. (1987). Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood, 62(5), pp. 454-7.
Cucchiara S, et al. Cisapride for Gastro-oesophageal Reflux and Peptic Oesophagitis. Arch Dis Child. 1987;62(5):454-7. PubMed PMID: 3300570.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cisapride for gastro-oesophageal reflux and peptic oesophagitis. AU - Cucchiara,S, AU - Staiano,A, AU - Capozzi,C, AU - Di Lorenzo,C, AU - Boccieri,A, AU - Auricchio,S, PY - 1987/5/1/pubmed PY - 1987/5/1/medline PY - 1987/5/1/entrez SP - 454 EP - 7 JF - Archives of disease in childhood JO - Arch. Dis. Child. VL - 62 IS - 5 N2 - Twenty children (age range 75 days-47 months) with reflux oesophagitis entered a random double blind trial in which they received either Cisapride (Janssen Pharmaceutical Ltd), a new prokinetic agent, or an identical placebo syrup. Diagnosis of gastro-oesophageal reflux was made by measurement of intraluminal oesophageal pH combined with manometry. Oesophagitis was assessed in all patients by histological examination of mucosal specimens taken during oesophagogastroduodenoscopy. Manometry, pH test, and endoscopy with biopsy examination were repeated at the end of the treatment period. Seventeen patients completed the trial, eight of whom were taking the drug and nine the placebo. Mean total clinical score and post-prandial reflux time (% of reflux) significantly improved in patients in the group given Cisapride but not in the group given placebo. Furthermore, there was a significant improvement of the histological oesophagitis score only in the children in the group given Cisapride, whereas placebo was ineffective. It is concluded that Cisapride is a useful agent both for the relief of symptoms of gastro-oesophageal reflux and for the healing of peptic oesophagitis in infancy. SN - 1468-2044 UR - https://www.unboundmedicine.com/medline/citation/3300570/Cisapride_for_gastro_oesophageal_reflux_and_peptic_oesophagitis_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/3300570/ DB - PRIME DP - Unbound Medicine ER -